Capsule vs tablet: which form of HRS-5965 works best?
NCT ID NCT06490991
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial tested 16 healthy adults to compare how well HRS-5965 is absorbed when taken as a capsule versus a tablet. The goal was to measure relative bioavailability on an empty stomach. This is a preliminary step before testing the drug in patients with blood or kidney disorders.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-5965
- What this could lead to
- If successful, this could help determine the best form (capsule or tablet) for future studies of HRS-5965 in conditions like paroxysmal nocturnal hemoglobinuria and IgA nephropathy.
- What could go wrong
- This is a very early, small study in healthy people, not patients. It only measures how the drug is absorbed, not whether it works for any disease. Results may not predict effectiveness or safety in patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA，IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ZhongShan Hospital FuDan University
Shanghai, Shanghai Municipality, 200032, China